JP2019508370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508370A5 JP2019508370A5 JP2018532465A JP2018532465A JP2019508370A5 JP 2019508370 A5 JP2019508370 A5 JP 2019508370A5 JP 2018532465 A JP2018532465 A JP 2018532465A JP 2018532465 A JP2018532465 A JP 2018532465A JP 2019508370 A5 JP2019508370 A5 JP 2019508370A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- ccl20
- level
- disease
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021172872A JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271156P | 2015-12-22 | 2015-12-22 | |
| US62/271,156 | 2015-12-22 | ||
| PCT/US2016/067120 WO2017112536A1 (en) | 2015-12-22 | 2016-12-16 | Ccl20 as a predictor of clinical response to il23-antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021172872A Division JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508370A JP2019508370A (ja) | 2019-03-28 |
| JP2019508370A5 true JP2019508370A5 (https=) | 2020-06-25 |
Family
ID=59091179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532465A Pending JP2019508370A (ja) | 2015-12-22 | 2016-12-16 | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
| JP2021172872A Pending JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021172872A Pending JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11220541B2 (https=) |
| EP (1) | EP3393515A4 (https=) |
| JP (2) | JP2019508370A (https=) |
| KR (1) | KR20180096633A (https=) |
| CN (1) | CN108472367A (https=) |
| AU (1) | AU2016379157A1 (https=) |
| BR (1) | BR112018012626A2 (https=) |
| CA (1) | CA3007098A1 (https=) |
| IL (1) | IL259704A (https=) |
| MX (1) | MX2018007589A (https=) |
| RU (1) | RU2018124603A (https=) |
| WO (1) | WO2017112536A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| JP6909208B2 (ja) | 2015-09-17 | 2021-07-28 | アムジェン インコーポレイテッド | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 |
| BR112021005467A2 (pt) | 2018-09-24 | 2021-06-22 | Janssen Biotech, Inc. | método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23 |
| CN108957014A (zh) * | 2018-09-27 | 2018-12-07 | 郑州大学第附属医院 | 结直肠癌血清标志物、表达评估方法、试剂盒及应用 |
| CN113710316A (zh) * | 2019-03-26 | 2021-11-26 | 阿斯特捷利康合作创业有限责任公司 | 适合于il23拮抗剂疗法的患者群体 |
| IL303198A (en) | 2020-11-30 | 2023-07-01 | Mindera Corp | Microneedle devices, methods and skin condition tests |
| CN113092652B (zh) * | 2021-03-19 | 2022-09-30 | 浙江工商大学 | 一种用于评估个体过敏程度的试剂盒 |
| CN114113630B (zh) * | 2021-11-24 | 2023-07-28 | 中南大学湘雅医院 | Serpinb3/b4作为靶点在玫瑰痤疮等炎症性皮肤病治疗药物中的应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318754D0 (en) | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5455160A (en) | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
| ES2225956T3 (es) | 1996-11-01 | 2005-03-16 | Magne K. Fagerhol | Procedimiento para la extraccion de proteinas. |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
| AU2005220910A1 (en) | 2004-03-05 | 2005-09-22 | Archemix Corp. | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| CA2565701A1 (en) | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| AU2006265002B2 (en) | 2005-06-30 | 2012-09-20 | Centocor, Inc. | Anti-IL-23 antibodies, compositions, methods and uses |
| DE602006015830D1 (de) | 2005-08-25 | 2010-09-09 | Lilly Co Eli | Anti-il-23-antikörper |
| EP3190125A1 (en) | 2005-08-31 | 2017-07-12 | Merck Sharp & Dohme Corp. | Engineered anti-il-23 antibodies |
| EP1954719A2 (en) | 2005-12-02 | 2008-08-13 | Genentech Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
| SI1971366T1 (sl) | 2005-12-29 | 2014-10-30 | Janssen Biotech, Inc. | Humana protitelesa anti-il-23, sestavki, postopki in uporabe |
| WO2007098065A2 (en) | 2006-02-17 | 2007-08-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Human sodium channel isoforms |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| AR065420A1 (es) | 2007-02-23 | 2009-06-03 | Schering Corp | Anticuerpos anti-il-23 p19 de ingenieria |
| EP2426145B1 (en) | 2007-02-23 | 2017-01-18 | Merck Sharp & Dohme Corp. | Engineered anti-il-23p19 antibodies |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| US7879553B2 (en) | 2008-03-14 | 2011-02-01 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
| CA2734919C (en) | 2008-08-27 | 2016-08-16 | Schering Corporation | Lyophilized formulations of engineered anti-il-23p19 antibodies |
| US20100221752A2 (en) | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
| WO2010042903A1 (en) | 2008-10-09 | 2010-04-15 | Alfagene Bioscience, Inc | Use and identification of biomarkers for gastrointestinal diseases |
| US20110212104A1 (en) * | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| CA2757237A1 (en) | 2009-04-01 | 2010-10-14 | Jane Elizabeth Clarkson | Anti-il-23 immunoglobulins |
| WO2010129964A1 (en) | 2009-05-08 | 2010-11-11 | The Board Of Trustees Of The University Of Illinois | Drug targets for prevention of arrhythmia in heart disease |
| EP2435480A1 (en) | 2009-05-27 | 2012-04-04 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
| WO2010151699A1 (en) | 2009-06-25 | 2010-12-29 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| BR112012012513A2 (pt) | 2009-11-25 | 2017-01-10 | Prometheus Lab Inc | método para diagnosticar síndrome do intestino irritável em um paciente, método para monitorar a progressão ou regressão da síndrome do intestino irritável em um paciente, e para designar uma terapia contra síndrome do intestino irritável a um paciente em necessidade do mesmo |
| HRP20171939T1 (hr) | 2010-01-15 | 2018-03-23 | Kirin-Amgen, Inc. | Formulacija protutijela i režimi terapije |
| EP2596022A4 (en) | 2010-07-20 | 2014-11-05 | Cephalon Australia Pty Ltd | SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23 |
| US8541180B1 (en) | 2010-10-11 | 2013-09-24 | Genova Diagnostics, Inc. | Compositions and methods for assessing gastrointestinal health |
| PE20141162A1 (es) | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| JP6116485B2 (ja) | 2011-01-06 | 2017-04-19 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 心臓性突然死に関連する方法において使用するためのｓｃｎ５ａスプライスバリアント |
| EP2710383B1 (en) | 2011-05-16 | 2017-01-11 | The University of Newcastle | Performance of a biomarker panel for irritable bowel syndrome |
| NO336551B1 (no) | 2011-06-21 | 2015-09-28 | Magne Fagerhol | Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve |
| NO20110895A1 (no) | 2011-06-21 | 2012-12-24 | Magne Fagerhol | Kompetitive S100A9 immunoanalyser |
| WO2013132338A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Competitive immunoassay for calprotectin |
| WO2013132347A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Improved elisa immunoassay for calprotectin |
| ES2716995T3 (es) | 2012-04-03 | 2019-06-18 | Univ Michigan Regents | Biomarcadores asociados con el síndrome del intestino irritable y la enfermedad de Crohn |
-
2016
- 2016-12-16 AU AU2016379157A patent/AU2016379157A1/en not_active Abandoned
- 2016-12-16 JP JP2018532465A patent/JP2019508370A/ja active Pending
- 2016-12-16 WO PCT/US2016/067120 patent/WO2017112536A1/en not_active Ceased
- 2016-12-16 MX MX2018007589A patent/MX2018007589A/es unknown
- 2016-12-16 CA CA3007098A patent/CA3007098A1/en not_active Abandoned
- 2016-12-16 CN CN201680075323.4A patent/CN108472367A/zh active Pending
- 2016-12-16 KR KR1020187017346A patent/KR20180096633A/ko not_active Withdrawn
- 2016-12-16 BR BR112018012626A patent/BR112018012626A2/pt not_active Application Discontinuation
- 2016-12-16 EP EP16879907.0A patent/EP3393515A4/en not_active Withdrawn
- 2016-12-16 RU RU2018124603A patent/RU2018124603A/ru not_active Application Discontinuation
- 2016-12-16 US US16/063,803 patent/US11220541B2/en active Active
-
2018
- 2018-05-30 IL IL259704A patent/IL259704A/en unknown
-
2021
- 2021-10-22 JP JP2021172872A patent/JP2022031643A/ja active Pending
- 2021-11-29 US US17/536,663 patent/US20220144935A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535394A5 (https=) | ||
| JP2019508370A5 (https=) | ||
| RU2018113694A (ru) | Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23 | |
| RU2018124603A (ru) | Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 | |
| Yamamoto et al. | Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases | |
| Ha et al. | Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis | |
| WO2011100637A1 (en) | Markers for determination of patient responsiveness | |
| CN104838270A (zh) | 用于预测和监测粘膜愈合的方法 | |
| Lee et al. | Isolated anti-Ro52 identifies a severe subset of Sjögren’s syndrome patients | |
| Majeed et al. | Serum profiles of pro-inflammatory and anti-inflammatory cytokines in non-hospitalized patients with mild/moderate COVID-19 infection. | |
| BR112016005745B1 (pt) | Biomarcadores para tuberculose | |
| EP3077818B1 (en) | Methods for predicting post-operative recurrence of crohn's disease | |
| Chen et al. | Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis | |
| TWI655433B (zh) | 川崎氏症之診斷與治療 | |
| Fouladseresht et al. | Anti-varicella zoster virus IgG and hsCRP levels correlate with progression of coronary artery atherosclerosis | |
| Jocić et al. | Interleukin 41 as a potential predictor of bio-therapy efficacy in patients with rheumatoid arthritis: A prospective observational study | |
| Codullo et al. | Validation of a new immunoenzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis | |
| JP2025533470A (ja) | Ｈｂｖの診断、予後判定及び治療の方法並びに製品 | |
| Gong et al. | Serum progranulin levels are elevated in patients with chronic hepatitis B virus infection, reflecting viral load | |
| Lian et al. | Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients | |
| EP3210027A1 (en) | Methods for predicting clinical outcomes in subjects afflicted with ulcerative colitis | |
| Ra et al. | Kinetics of Serological Response in Patients with Severe Fever with Thrombocytopenia Syndrome. Viruses 2021, 13, 6 | |
| WO2015166461A1 (en) | Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels | |
| Dawood et al. | Assessment Association between IFN-β2, AST and Natural Course of Infections with Hepatitis A and C Viruses | |
| Hussein et al. | Clinical Relevance Of Anti-Cyclic Citrullinated Peptide Antibodies In Rheumatoid Arthritis |